TITLE

VARIATION IN HELICOBACTER PYLORI STRAINS FROM IRAN AND ZAMBIA

AUTHOR(S)
Raeiszadeh, M.; Fernando, N.; Holton, J.; Vaira, D.; Siavoshi, F.; Hosseini, A.; Kelly, P.
PUB. DATE
April 2003
SOURCE
Gut;Apr2003 Supplement 1, Vol. 52, pA79
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Different genotypes of H pylori have been observed in different locations of the world and identification of these genotypes may be important for understanding the clinical outcome of infection, the efficacy of antibiotic treatment, laboratory diagnosis, and possibly human migration patterns. Data on the vacA diversity from Iran and Africa are sparse. We compared the vacuolating cytotoxin alleles (vacA) and the cytotoxin associated gene A (cagA) in H pylori isolates from Iran and Zambia by means of PCR. A total of 31 H pylori isolates were studied from Iranian dyspeptic and 23 from Zambian dyspeptic patients. There was an equal distribution of s1 and s2 alleles in Iran, where slc was the predominant s1 subtype (10 of 16 s1 strains) with the m2 region predominating (26 out of 26 strains, with 5 stains unable to be typed in the "m" region). Isolates from Zambia mostly carried the sl allele (21 out of 23) with the s1 b allele being the most frequent (18 out of 21) and in the m region the m1 allele predominating (17 out of 21) with 2 stains non-typable for the m region. Using primer pairs for cagA 3' region, the percentages of cagA positive strains in Iran and Zambia were 41% (13 out of 31) and 86% (20 out of 23), respectively. Most of the cagA positive strains (85%) from Iran were of the non-Asian type and only two isolates were of the pure East Asian type. All of the 20 cagA positive strains from Zambia were of the non-Asian type and had the s1 allele. In Iran the cagA gene was found at a higher frequency in the s1 allele type (11 out of 16) as compared to the s2 strains (2 out of 15). Overall there was a strong association between the cagA marker and the s1 allele (p < 0.001).
ACCESSION #
9747810

 

Related Articles

  • Antibiotic-Resistant H. pylori Infection and Its Treatment. Qureshi, Waqar A.; Graham, David Y. // Current Pharmaceutical Design;Oct2000, Vol. 6 Issue 15, p1537 

    Helicobacter pylori infection causes progressive damage to gastric mucosa and results in serious disease such as peptic ulcer disease, MALT lymphoma, or gastric adenocarcinoma in 20% to 30% of patients. The current approach is to make a firm diagnosis, give combination antibiotic and...

  • Bismuth based regimes should be first line therapy for Helicobacter pylori eradication. Iakovenko, E.P.; Grigoriev, P.; Yakovenko, A.V.; Bikbavova, R.; Anashkin, V.; Anaeva, T.; Aldiyarova, M.; Soluyanova, I. // Gut;Sep2002 Supplement 2, Vol. 51, pA92 

    Increasing of antibiotic resistance of Helicobacter pylori (Hp), ability of bismuth compounds overcome it may have a significant clinical impact on efficacy and choice of current anti-Hp regimens eradication Aim: to compare the eradication rate of Hp-infection in 1997 and in 2001 year (yr) using...

  • Past Antibiotic Use Affects Resistance and Outcomes of Helicobacter pylori Infection. Mcmahon, B.J.; Hennessy, T.W.; Bensler, J.M.; Bruden, D.L.; Parkinson, A.J.; Morris, J.M.; Reasonover, A.L.; Huriburt, D.A.; Bruce, M.G.; Sacco, F.; Butler, J.C. // Annals of Internal Medicine;9/16/2003, Vol. 139 Issue 6, pI10 

    Helicobacter pylori is a common type of bacteria that usually infects people during their childhoods. In most cases, the infection does not cause problems. However, some people with H. pylori infection get inflammation or ulcers in the stomach or upper intestine. Doctors treat inflammation and...

  • Failure of Azythromycin to Eradicate Campylobacter pylori from the Stomach because of Acquired Resistance during Treatment. Glupczynski, Youri; Burette, Alain // American Journal of Gastroenterology;Jan1990, Vol. 85 Issue 1, p98 

    Presents a study which investigated the efficacy of azythromycin in eliminating Campylobacter pylori from the stomach in patients with antral gastritis. Dosage of azythromycin given to dyspeptic patients; Emergence of resistance to azythromycin; Efficacy of macrolides in treating Campylobacter...

  • Limited Efficacy of Omeprazole--based Dual and Triple Therapy for Helicobacter pylori: A Randomized Trial Employing "Optimal" Dosing. Laine, Loren; Stein, Craig; Neil, Garry // American Journal of Gastroenterology;Sep1995, Vol. 90 Issue 9, p1407 

    Objectives: To evaluate the efficacy and side effects of dual omeprazole/amoxicillin therapy for Helicobacter pylori given in "optimal" fashion (omeprazole twice a day, 3 g of amoxicllin daily, drugs started concurrently, 2 wk of therapy) and to assess the utility of adding a second antibiotic,...

  • The Long-Term Reinfection Rate and the Course of Duodenal Ulcer Disease After Eradication of Helicobacter pylori in a Developing Country. Rollan, Antonio; Giancaspero, Rossana; Fuster, Francisco; Acevedo, Claudia; Figueroa, Cecilia; Hola, Karen; Schulz, Marcela; Duarte, Ignacio // American Journal of Gastroenterology;Jan2000, Vol. 95 Issue 1, p50 

    OBJECTIVE: The aim of this study was to evaluate the effect of Helicobacter pylori (H. pylori) eradication on the natural history of duodenal ulcer disease and the reinfection rate after treatment in a developing country. METHODS: A total of 111 H. pylori-infected patients with...

  • Treating peptic ulcers: A whole new ball game. Kuznar, Wayne // Modern Medicine;Apr94, Vol. 62 Issue 4, p11 

    Reports on the growing number of peptic ulcer patients undergoing antibiotic treatment. Helicobacter pylori as the cause of almost all peptic ulcers; Comparison between antibiotic and antisecretory therapy; Use of endoscopic biopsy in diagnosing Helicobacter pylori infections. INSET: On deck:...

  • Ulcer-causing bacterium now detectable by breath test.  // Medical Update;Nov96, Vol. 20 Issue 5, p1 

    Reports that the United States Food & Drug Administration (FDA) has approved the first antibiotic treatment for peptic ulcers. Combining of omeprazole and clarithromycin; Eradication of the Helicobacter pylori infection.

  • The Genetic Gymnastics of Our Indigenous Microbes. Blaser, Martin J. // New England Journal of Medicine;6/27/2002, Vol. 346 Issue 26, p2083 

    Focuses on the colonization of the stomach by Helicobacter pylori. Efforts of Israel and colleagues to define the genes in H. pylori within a given host; Evaluation of the frequency of resistance in the stomach and how the variants compete in the stomach against the wild-type strain when the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics